- Home
- MDBH vs PRLD Comparison
MDBH vs PRLD Comparison
Compare MDBH & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDBH
- PRLD
- Stock Information
- Founded
- MDBH 1997
- PRLD 2016
- Country
- MDBH United States
- PRLD United States
- Employees
- MDBH N/A
- PRLD N/A
- Industry
- MDBH
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- MDBH
- PRLD Health Care
- Exchange
- MDBH Nasdaq
- PRLD Nasdaq
- Market Cap
- MDBH 42.1M
- PRLD 48.6M
- IPO Year
- MDBH 2023
- PRLD 2020
- Fundamental
- Price
- MDBH $5.37
- PRLD $0.78
- Analyst Decision
- MDBH
- PRLD Strong Buy
- Analyst Count
- MDBH 0
- PRLD 2
- Target Price
- MDBH N/A
- PRLD $4.50
- AVG Volume (30 Days)
- MDBH 4.7K
- PRLD 221.0K
- Earning Date
- MDBH 08-12-2025
- PRLD 08-11-2025
- Dividend Yield
- MDBH N/A
- PRLD N/A
- EPS Growth
- MDBH N/A
- PRLD N/A
- EPS
- MDBH 0.84
- PRLD N/A
- Revenue
- MDBH $3,574,131.00
- PRLD $7,000,000.00
- Revenue This Year
- MDBH N/A
- PRLD N/A
- Revenue Next Year
- MDBH N/A
- PRLD N/A
- P/E Ratio
- MDBH $6.07
- PRLD N/A
- Revenue Growth
- MDBH N/A
- PRLD N/A
- 52 Week Low
- MDBH $3.61
- PRLD $0.61
- 52 Week High
- MDBH $12.00
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- MDBH 62.86
- PRLD 42.16
- Support Level
- MDBH $4.30
- PRLD $0.77
- Resistance Level
- MDBH $4.73
- PRLD $0.84
- Average True Range (ATR)
- MDBH 0.30
- PRLD 0.07
- MACD
- MDBH 0.08
- PRLD -0.02
- Stochastic Oscillator
- MDBH 74.33
- PRLD 16.04
About MDBH MDB Capital Holdings LLC common
MDB Capital Holdings LLC is an investment holding company that operates through its subsidiaries and focuses on early-stage technology companies through public offerings. The company's purpose is to engage with companies holding visionary technology, inventors, and technology entrepreneurs. The Company operates in two reportable segments: a broker dealer & intellectual property service, and the technology development segment. The broker dealer & intellectual property service segment, which derives key revenue, is engaged in conducting private and public securities offerings and offers in-depth patent research used for investment banking due diligence.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.